Opus Genetics, Inc. (IRD)
(Delayed Data from NSDQ)
$1.07 USD
-0.04 (-3.60%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.09 +0.02 (1.87%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IRD 1.07 -0.04(-3.60%)
Will IRD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IRD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRD
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates
IRD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates
Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Other News for IRD
Opus Genetics (IRD) Partners with Global RDH12 Alliance for Gene Therapy Advancement | IRD ...
Opus Genetics (IRD) Forms Strategic Partnership to Advance Gene Therapy | IRD Stock News
Opus Genetics, Global RDH12 Alliance partner to advance RDH12 gene therapy
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | IRD Stock News